Compassionate Use Pathways for Tigilanol Tiglate: How Patients Access Unapproved Cancer Drugs
Compassionate use and expanded access programmes could allow cancer patients to receive tigilanol tiglate before formal Phase III approval — here is how the regulatory framework works.
When Patients Cannot Wait for Phase III
For patients with advanced or treatment-resistant cancers, the standard drug approval timeline — often spanning a decade or more — can feel impossibly long. Compassionate use programmes, also known as expanded access, exist precisely for this reason: they provide a regulated pathway for seriously ill patients to access investigational drugs that have not yet received full marketing authorisation.[1]
Tigilanol tiglate (EBC-46), the diterpene ester derived from Fontainea picrosperma, is currently advancing through human clinical trials following its successful veterinary approval as Stelfonta.[2] As Phase I/II data continues to show favourable safety profiles, the question of pre-approval patient access becomes increasingly relevant.
How Compassionate Use Works in Practice
Both the FDA and EMA maintain formal mechanisms for compassionate use. The FDA's expanded access programme allows physicians to request investigational drugs for individual patients or small cohorts when three conditions are met: the patient has a serious or life-threatening condition, no comparable alternative therapy exists, and the potential benefit justifies the potential risks.[3]
The EMA operates a similar framework through its compassionate use recommendations, which allow member states to grant access to medicines undergoing clinical development. For intratumoral agents like tigilanol tiglate, these pathways are particularly significant because the drug's localised mechanism of action may present a different risk-benefit profile compared to systemic therapies.[4]
What the Veterinary Precedent Tells Us
Stelfonta's regulatory journey provides instructive parallels. The drug moved from preclinical research to conditional veterinary approval based on demonstrated efficacy in canine mast cell tumours, with response rates exceeding 75% in pivotal studies.[5] The FDA granted full approval in 2020, and the EMA followed with authorisation for the European market.[6]
This veterinary track record strengthens the argument for expanded access in human oncology. Regulators evaluating compassionate use requests look at the totality of evidence — and a drug with established veterinary efficacy, known pharmacokinetics, and Phase I human safety data represents a stronger case than a molecule with only preclinical work behind it.
Patient Eligibility and the Treating Physician's Role
Compassionate use is not a blanket programme. Each request must come from a treating physician who provides clinical justification for why the patient qualifies. For tigilanol tiglate, likely candidates would include patients with accessible solid tumours who have exhausted standard treatment options.[7]
The treating physician bears responsibility for patient monitoring, adverse event reporting, and compliance with institutional review board requirements. QBiotics Group, as the drug sponsor, must also agree to provide the investigational product — a decision that balances humanitarian access against the need to preserve drug supply for ongoing clinical trials.[8]
The Broader Significance for Immune-Activating Therapies
Tigilanol tiglate is not a conventional cytotoxic drug. Its mechanism involves PKC activation, vascular disruption, and immune cascade recruitment — a multimodal action that distinguishes it from both traditional chemotherapy and modern checkpoint inhibitors.[9] This immune-activating profile raises interesting questions about compassionate use: patients who are refractory to checkpoint inhibitors might respond to a drug that engages the immune system through an entirely different pathway.
As clinical data matures and regulatory agencies accumulate experience with intratumoral immunotherapies, compassionate use pathways for tigilanol tiglate may become an increasingly important bridge between clinical trials and eventual marketing approval.
References
- FDA Orphan Drug Designation Overview. FDA.gov ↗
- FDA approves Stelfonta for canine mast cell tumours (2020). FDA.gov ↗
- FDA Expanded Access programme requirements. FDA.gov ↗
- EMA Stelfonta veterinary authorisation (EPAR). EMA.europa.eu ↗
- Boyle et al. (2014) Intratumoural injection of EBC-46 in canine tumours. PLOS ONE. PubMed ↗
- EMA marketing authorisation for Stelfonta in the EU. EMA.europa.eu ↗
- Active clinical trials for tigilanol tiglate. ClinicalTrials.gov ↗
- QBiotics Group — EBC-46 development programme. QBiotics.com ↗
- Newton (2018) PKC activation and immune signalling in tumour biology. PubMed ↗
